| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Cannabisin B targets the AKT/mTOR signaling pathway. It induces autophagic cell death by inhibiting the AKT/mTOR pathway and causes S-phase cell cycle arrest. It may also modulate gene expression in neural cells.
|
|---|---|
| ln Vitro |
Cannabisin B possesses considerable antiproliferative activity against cancer cells, including the HepG2 hepatoblastoma cell line. It induces autophagic cell death and causes cell cycle arrest in the S phase, demonstrating its potential as a chemopreventive agent.
|
| ln Vivo |
Dedicated in vivo efficacy studies for Cannabisin B are not extensively documented in standard supplier profiles. Most of its biological characterization is derived from in vitro experiments. Further animal studies are required to confirm its therapeutic potential.
|
| Enzyme Assay |
In vitro binding assays are not typically performed for this natural product. Instead, pathway activity is assessed. Western blotting is used to detect phosphorylation levels of AKT and mTOR in cell lysates following treatment. Autophagy markers (e.g., LC3-II conversion) are also measured.
|
| Cell Assay |
HepG2 cells are cultured and treated with Cannabisin B. Cell proliferation is measured by MTT assay. Cell cycle analysis is performed by flow cytometry after propidium iodide staining. Autophagy is assessed by monodansylcadaverine (MDC) staining or LC3 puncta visualization.
|
| Animal Protocol |
Dedicated in vivo protocols for Cannabisin B are not well-documented. A standard protocol would involve xenograft of HepG2 cells in nude mice, followed by intraperitoneal or oral administration of the compound. Tumor growth would be monitored, and tumor tissues would be analyzed for AKT/mTOR pathway markers.
|
| ADME/Pharmacokinetics |
PK properties for Cannabisin B are not extensively documented. As a natural lignan with a molecular weight of 596.64 g/mol and multiple hydroxyl groups, its oral bioavailability may be limited. Extensive ADME studies have not been reported in standard profiles.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for Cannabisin B is not available. As a natural product, it is not intended for clinical use and comprehensive animal toxicology studies have not been performed. Standard laboratory handling precautions are adequate.
|
| References | |
| Additional Infomation |
Cannabinoid B has been reported in cannabis and Xylopia aethiopica, and data are available. See also: Cannabis subspecies. Top of rice (partial).
Cannabisin B serves as a reference standard for the analysis of hemp seed polyphenols. Its ability to induce autophagy distinct from apoptosis makes it an interesting tool for studying cell death mechanisms. It is not an approved drug. |
| Molecular Formula |
C34H32N2O8
|
|---|---|
| Molecular Weight |
594.65
|
| Exact Mass |
596.215
|
| CAS # |
144506-17-2
|
| PubChem CID |
71448963
|
| Appearance |
White to light yellow solid powder
|
| Boiling Point |
1016.3±65.0 °C(Predicted)
|
| LogP |
4.2
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
44
|
| Complexity |
992
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC(=CC=C1CCNC(=O)[C@@H]2[C@H](C3=CC(=C(C=C3C=C2C(=O)NCCC4=CC=C(C=C4)O)O)O)C5=CC(=C(C=C5)O)O)O
|
| InChi Key |
XENYXHLAFMZULS-ACHIHNKUSA-N
|
| InChi Code |
InChI=1S/C34H32N2O8/c37-23-6-1-19(2-7-23)11-13-35-33(43)26-15-22-17-29(41)30(42)18-25(22)31(21-5-10-27(39)28(40)16-21)32(26)34(44)36-14-12-20-3-8-24(38)9-4-20/h1-10,15-18,31-32,37-42H,11-14H2,(H,35,43)(H,36,44)/t31-,32-/m0/s1
|
| Chemical Name |
(1S,2R)-1-(3,4-dihydroxyphenyl)-6,7-dihydroxy-2-N,3-N-bis[2-(4-hydroxyphenyl)ethyl]-1,2-dihydronaphthalene-2,3-dicarboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6817 mL | 8.4083 mL | 16.8166 mL | |
| 5 mM | 0.3363 mL | 1.6817 mL | 3.3633 mL | |
| 10 mM | 0.1682 mL | 0.8408 mL | 1.6817 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
